BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2015; 21(13): 3843-3849 [PMID: 25852268 DOI: 10.3748/wjg.v21.i13.3843] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Wang Y, Guo X, He Y, Zhou J, Lv Q, Huang X, Li X. Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:709278. [PMID: 34540675 DOI: 10.3389/fonc.2021.709278] [Reference Citation Analysis]
2 Abdelmaksoud AHK, Abdelaziz AO, Nabeel MM, Hamza I, Elbaz TM, Shousha HI, Abdelhady RSM, Lithy R. Hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein thrombosis: a case-control study. Clin Radiol 2021;76:709.e1-6. [PMID: 34116796 DOI: 10.1016/j.crad.2021.03.022] [Reference Citation Analysis]
3 Guo W, Gao J, Zhuang W, Wu Z, Li B, Chen S. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study. JGH Open 2020;4:477-83. [PMID: 32514457 DOI: 10.1002/jgh3.12285] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Wang Z, Zhang H, Zhou J, Zhang X, Chen L, Chen K, Huang Z. Eriocitrin from lemon suppresses the proliferation of human hepatocellular carcinoma cells through inducing apoptosis and arresting cell cycle. Cancer Chemother Pharmacol 2016;78:1143-50. [PMID: 27766389 DOI: 10.1007/s00280-016-3171-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
5 Goyal L, Qadan M, Zhu AX. Another Treatment Option for Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis in China. JAMA Oncol 2019;5:938-9. [PMID: 31070694 DOI: 10.1001/jamaoncol.2019.0249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Wu XL, Chen Y, Kong WC, Zhao ZQ. Amyloid precursor protein regulates 5-fluorouracil resistance in human hepatocellular carcinoma cells by inhibiting the mitochondrial apoptotic pathway. J Zhejiang Univ Sci B 2020;21:234-45. [PMID: 32133800 DOI: 10.1631/jzus.B1900413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Lee J, Sung PS, Yang H, Lee SK, Nam HC, Yoo SH, Lee HL, Kim HY, Lee SW, Kwon JH, Jang JW, Kim CW, Nam SW, Bae SH, Choi JY, Yoon SK. A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC. J Clin Med 2020;9:E4121. [PMID: 33371271 DOI: 10.3390/jcm9124121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
8 Choi JH, Chung WJ, Bae SH, Song DS, Song MJ, Kim YS, Yim HJ, Jung YK, Suh SJ, Park JY, Kim DY, Kim SU, Cho SB. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2018;82:469-478. [PMID: 29982870 DOI: 10.1007/s00280-018-3638-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
9 Lee JH, Moon H, Han H, Lee IJ, Kim D, Lee HJ, Ha SW, Kim H, Chung JW. Antitumor Effects of Intra-Arterial Delivery of Albumin-Doxorubicin Nanoparticle Conjugated Microbubbles Combined with Ultrasound-Targeted Microbubble Activation on VX2 Rabbit Liver Tumors. Cancers (Basel) 2019;11:E581. [PMID: 31022951 DOI: 10.3390/cancers11040581] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
10 Hsiao J, Tsai C, Liang T, Chiang C, Liang H, Chen I, Chen Y, Chang P, Chou N, Wang B. Adjuvant hepatic arterial infusion chemotherapy is beneficial for selective patients with Hepatocellular carcinoma undergoing surgical treatment. International Journal of Surgery 2017;45:35-41. [DOI: 10.1016/j.ijsu.2017.07.071] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
11 Kim M, Powers CA, Curtin LI, Fisher DT, Sexton S, Gurova KV, Skitzki JJ, Iyer RV. A Translational Hepatic Artery Infusion (HAI) Model for Hepatocellular Carcinoma in Woodchucks. J Surg Res. 2020;251:126-136. [PMID: 32143057 DOI: 10.1016/j.jss.2020.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Liu S, Lai J, Lyu N, Xie Q, Cao H, Chen D, He M, Zhang B, Zhao M. Effects of Antiviral Therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma Patients Undergoing Hepatic Artery Infusion Chemotherapy. Front Oncol 2020;10:582504. [PMID: 33614477 DOI: 10.3389/fonc.2020.582504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Takami T, Yamasaki T, Saeki I, Matsumoto T, Suehiro Y, Sakaida I. Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World J Gastroenterol 2016; 22(32): 7252-7263 [PMID: 27621572 DOI: 10.3748/wjg.v22.i32.7252] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
14 Tsai WL, Sun WC, Chen WC, Chiang CL, Lin HS, Liang HL, Cheng JS. Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma. Medicine (Baltimore) 2020;99:e21489. [PMID: 32769883 DOI: 10.1097/MD.0000000000021489] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ikeda M, Okusaka T, Sato Y, Furuse J, Mitsunaga S, Ueno H, Morizane C, Inaba Y, Kobayashi T, Arai Y. A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma. Japanese Journal of Clinical Oncology 2017;47:512-9. [DOI: 10.1093/jjco/hyx038] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
16 Gao J, Zhen R, Liao H, Zhuang W, Guo W. Pharmacokinetics of continuous transarterial infusion of 5-fluorouracil in patients with advanced hepatocellular carcinoma. Oncol Lett. 2018;15:7175-7181. [PMID: 29725440 DOI: 10.3892/ol.2018.8242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Chang WT, Bow YD, Fu PJ, Li CY, Wu CY, Chang YH, Teng YN, Li RN, Lu MC, Liu YC, Chiu CC. A Marine Terpenoid, Heteronemin, Induces Both the Apoptosis and Ferroptosis of Hepatocellular Carcinoma Cells and Involves the ROS and MAPK Pathways. Oxid Med Cell Longev 2021;2021:7689045. [PMID: 33488943 DOI: 10.1155/2021/7689045] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
18 Chen F, Fang Y, Zhao R, Le J, Zhang B, Huang R, Chen Z, Shao J. Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma. Eur J Med Chem 2019;179:916-35. [PMID: 31306818 DOI: 10.1016/j.ejmech.2019.06.070] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
19 Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 2019; 25(28): 3704-3721 [PMID: 31391767 DOI: 10.3748/wjg.v25.i28.3704] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
20 Ma D, Wang J, Liu L, Chen M, Wang Z. Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study. BMC Cancer 2020;20:936. [PMID: 32993568 DOI: 10.1186/s12885-020-07447-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
21 Wang Z, Chen W, Zhang X, Cai Z, Huang W. A long way to the battlefront: CAR T cell therapy against solid cancers. J Cancer 2019;10:3112-23. [PMID: 31289581 DOI: 10.7150/jca.30406] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
22 Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM. A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemother Pharmacol 2018;82:877-85. [PMID: 30182147 DOI: 10.1007/s00280-018-3680-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Kang MK, Park JG, Lee HJ. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article. Medicine (Baltimore). 2018;97:e0611. [PMID: 29703062 DOI: 10.1097/md.0000000000010611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
24 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
25 Ikuta S, Aihara T, Yamanaka N. Efficacy of sequential sorafenib plus hepatic arterial infusion chemotherapy in patients with Barcelona Clinic Liver Cancer stage B and C hepatocellular carcinoma: a retrospective single-institution study. Contemp Oncol (Pozn) 2018;22:165-71. [PMID: 30455588 DOI: 10.5114/wo.2018.78948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]